Alexis Talbot

23PUBLICATIONS
152CO-AUTHORS
Predictive and prognostic markersMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Micro- and nanosystemsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jun 19, 2026
CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.

|Feb 25, 2026
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).

Alexis Talbot, Bernard Delcour, Laurent Gillot

|Feb 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla, Lionel Karlin, Jérôme Lambert

|Nov 24, 2025
Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function.

Vincent Allain, Allison G Rothrock, Pierre-Louis Bernard

|Nov 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar

|Oct 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Philippe Moreau, Cyrille Hulin, Alexis Talbot

Pageof 4

Frequent Collaborators

6 joint publications

Justin Eyquem

5 joint publications

Jill Corre

5 joint publications

Aurore Perrot

4 joint publications

Mohamad Mohty